ArticleTranslational stroke research2026
A Phenotype-Based Score to Prioritize RNF213 p.R4810K Genotyping in Isolated Intracranial Steno-Occlusive Disease.
Article in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRing finger protein 213 (RNF213) p.R4810K is a genetic susceptibility factor for intracranial arteriopathies. In patients with isolated intracranial arterial steno-occlusive disease (ICAD) without Moyamoya disease (MMD), we developed a phenotype-based triage score to prioritize RNF213 genotyping by enriching the p.R4810K carriage probability.
methodsWe retrospectively analyzed 753 patients with isolated ICAD involving the distal internal carotid artery or middle cerebral artery M1 segment who underwent RNF213 genotyping between January 2010 and November 2022, excluding definite MMD or significant extracranial steno-occlusion. A prespecified score incorporated anterior cerebral artery (ACA) laterality (0/1/2), tandem lesion burden ≥ 3 (0/1), and MMD family history (0/1; weighted ×4). Discrimination, prespecified thresholds (≥ 3 and ≥ 4), and bootstrap-corrected calibration were assessed, with external application in an independent cohort.
resultsRNF213 p.R4810K was identified in 289 patients (38.4%). MMD family history showed the strongest association with carriage (adjusted odds ratio [OR] 8.34, 95% confidence interval [CI]: 4.15-16.77, p < 0.001), followed by tandem burden ≥ 3 (adjusted OR 1.76, 95% CI: 1.15-2.69, p = 0.009) and ACA laterality (adjusted OR 1.74, 95% CI: 1.35-2.23, p < 0.001). The score showed moderate discrimination (internal area under the curve [AUC] 0.720; external AUC 0.708). A cutoff ≥ 3 restricted genotyping to 33.5% of patients while capturing 55.7% of carriers, reducing genotyping workload by 66.5%. A cutoff ≥ 4 increased the positive predictive value to 81.7% with 97.6% specificity.
conclusionsIn clinically selected isolated ICAD, a phenotype-based score incorporating lesion distribution and family history may help prioritize RNF213 genotyping and improve genotyping yield in resource-limited settings.
Indexed as
Identifiers
42541694What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.